| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 141, 519-524, Copyright © 1992 by American Society for Investigative Pathology
REVIEWS |
RS Kerbel
Cancer Research Division, Sunnybrook Health Science Center, Toronto, Ontario, Canada.
Evidence is briefly reviewed, primarily in the context of human melanoma, which suggests that acquisition of resistance to multiple, structurally diverse, growth inhibitory cytokines occurs during malignant tumor progression. A similar pleiotrophy appears to occur with respect to growth factor independence. Also discussed is the notion that growth factors that behave as inhibitors for early-stage, benign tumor cells can 'switch' so as to function as mitogens for tumor cells from more advanced stages of disease progression, i.e., when the cells acquire competence for metastasis. The combined phenotypes of 'multicytokine resistance' and 'multi-growth factor independence' help provide tumor cells with the competence to grow in the mesenchymes of the primary organ site and in distant organs.
This article has been cited by other articles:
![]() |
J. K. L. Woodward, S. R. Elshaw, A. K. Murray, C. E. Nichols, N. Cross, D. Laws, I. G. Rennie, and K. Sisley Stimulation and Inhibition of Uveal Melanoma Invasion by HGF, GRO, IL-1{alpha} and TGF-{beta} Invest. Ophthalmol. Vis. Sci., October 1, 2002; 43(10): 3144 - 3152. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Brender, M. Nielsen, K. Kaltoft, G. Mikkelsen, Q. Zhang, M. Wasik, N. Billestrup, and N. Odum STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma Blood, February 15, 2001; 97(4): 1056 - 1062. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Marx Cellular changes on the route to metastasis Science, January 29, 1993; 259(5095): 626 - 629. |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |